TY - T1的风险因素的副作用异烟肼、利福平、吡嗪酰胺的病人住院肺结核JF -欧洲呼吸杂志》乔和J SP - 2026 LP - 2030欧元六世- 9 - 10盟Schaberg T非盟- Rebhan K AU -脉,H Y1 - 1996/10/01 UR - //www.qdcxjkg.com/content/9/10/2026.abstract N2 -本研究的目的是确定当前的副作用发生率严重到足以让不宽容对公开的标准疗法与异烟肼,利福平,吡嗪酰胺的病人由于肺结核住院。五百一十九已被证实的肺结核患者,最初对公开接受标准治疗,回顾性研究传染病系的教学医院胸部。严重的副作用的发生率相关治疗,导致最终终止三个标准药物之一,是衡量和偏狭的风险因素进行分析。最后终止异烟肼、利福平、吡嗪酰胺因为严重的副作用是必要的在121年的519名患者(23%)。最严重的副作用导致最终终止的一种药物肝毒性(11%)、疹(6%),和关节痛(2%)。吡嗪酰胺表现出更严重的副作用(15%)比异烟肼(7%)和利福平(1.5%)。重大风险因素不宽容多元分析后的标准治疗肝炎的历史(比值比(或)3.4;95%置信区间1.6 - -7.6(95%置信区间);p = 0.0026) and an age > or = 60 yrs (OR 1.9; 95% CI 1.2-3.2; p = 0.017). Both of these risk factors were also significantly associated with the intolerance of pyrazinamide (history of hepatitis: OR 2.5; 95% CI 1.4-4.3; p = 0.0045; age > or = 60 yrs: OR 2.1, 95% CI 1.3-3.5; p = 0.0029) but not of isoniazid and rifampin. The side-effects of standard antituberculosis therapy are frequent in hospitalized patients aged > or = 60 yrs or with a history of previous hepatitis, and are probably due to pyrazinamide rather than to isoniazid or rifampin. ER -